Welcure Drugs and Pharmaceuticals Share Price Hits Upper Circuit After ₹85.6 Cr Export Order Surge

Market Performance

Welcure Drugs and Pharmaceuticals’ share price surged 5% on Tuesday, hitting the upper circuit at ₹14.28.

This price jump came after the announcement of two major export sourcing orders totaling ₹85.6 Crore.

• Monthly gain: Over 26.71% in the last month
• 6-month growth: Over 29%, outperforming in a volatile market

The stock is currently trading below ₹20, yet continues to show significant upside momentum in the small-cap pharmaceutical segment.

Main News

Welcure Drugs and Pharmaceuticals Limited secured two export sourcing deals worth approximately ₹85.6 Crore, with each deal valued at ₹42.8 Crore.

These contracts were signed with international partners Giant Exim and Ravina International.

According to the company’s filing to the stock exchange:

• These deals are structured on a fee-based revenue model
• No inventory or logistics risk is involved
• Commission income will be recognized with each lot dispatched
• Expected to boost margins in the current quarter

The company is also in advanced negotiations with other international clients for similar mandates.

Company Details

Name: Welcure Drugs & Pharmaceuticals Ltd

Founded: 1992

Headquarters: New Delhi, India

Sector: Pharmaceuticals

Product Range:

• Tablets
• Capsules
• Dry syrups
• Other medicinal formulations

Welcure is known for its diversified portfolio and strategic focus on export sourcing and fee-based models. The company also maintains a debt-free capital structure.

Financial Performance – Q4 FY2025

Revenue

• Q4 Sales: ₹21.21 Crore
• Same quarter last year: ₹0 Crore
• A strong recovery in top-line performance

Net Profit

• Q4 Net Profit: ₹2.54 Crore
• Previous Quarter (Q3): Net loss of ₹0.02 Crore
• Full-Year Net Profit: ₹2.17 Crore
• Last Year (FY24): Net loss of ₹0.17 Crore
• Turnaround performance from loss to profit

Summary of the Article

• Welcure Drugs and Pharmaceuticals’ share price surged 5% to ₹14.28 after winning two export orders worth ₹85.6 Crore
• These deals are structured as fee-based agreements, minimizing operational risk
• The company reported ₹2.54 Crore net profit in Q4 FY25, reversing previous losses
• Sales improved to ₹21.21 Crore from zero in the same quarter last year
• Welcure continues to expand its export presence and is currently debt-free